Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lung Neoplasms 12Multiple Myeloma 11Lymphoma 10Neoplasm Metastasis 9Melanoma 7Leukemia, Myeloid, Acute 7Prostatic Neoplasms 6Neuroblastoma 6Carcinoma, Non-Small-Cell Lung 6Wilms Tumor 5Medulloblastoma 5Lymphoma, Non-Hodgkin 5Fallopian Tube Neoplasms 5Burkitt Lymphoma 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Rhabdoid Tumor 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Osteosarcoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Histiocytosis, Langerhans-Cell 4Hepatoblastoma 4Glioma 4Ependymoma 4Central Nervous System Neoplasms 4Sarcoma, Kaposi 3Sarcoma 3

Interventions

fludarabine phosphate 19Whole-Body Irradiation 15Peripheral Blood Stem Cell Transplantation 15Mycophenolic Acid 15Tacrolimus 12Cyclosporine 11Cyclophosphamide 11Antilymphocyte Serum 11Busulfan 10Rituximab 7Methotrexate 7Etoposide 6Melphalan 5Flow Cytometry 5Radiotherapy 4Panobinostat 4Lenalidomide 4Filgrastim 4Everolimus 4Dexamethasone 4Calcium Dobesilate 4thymoglobulin 3romidepsin 3pembrolizumab 3mogamulizumab 3fludarabine 3Therapeutics 3Sirolimus 3In Situ Hybridization, Fluorescence 3Immunohistochemistry 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sezary Syndrome × Specimen Handling × Clear all
NCT04541017 2025-10-16

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

National Cancer Institute (NCI)

Phase 1/2 Terminated
8 enrolled 8 charts
Lymphoid

Mycosis Fungoides, Sezary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡